Strides Pharma in South Africa

Strides Pharma Strengthens South African Operations Amid Strategic Developments

Johannesburg, South Africa – July 23, 2025

Strides Pharma Science Limited has recently undertaken significant strategic initiatives to bolster its presence and operational efficiency in South Africa. These developments underscore the company’s commitment to enhancing its footprint in the region’s pharmaceutical sector.

Consolidation of South African Operations

In March 2024, Strides Pharma consolidated its South African operations by transferring a 100% stake in Strides Pharma (SA) Pty Ltd to its subsidiary, Trinity Pharma Proprietary Limited. This move, valued at ZAR 21.73 million, aims to achieve operational synergies and streamline business processes within the group. The payment for this acquisition is structured to be completed in cash by March 2027, with provisions for early settlement under specific conditions. (capitalmarket.com)

Securing Working Capital Financing

In December 2023, Trinity Pharma secured a credit facility of ZAR 70 million (approximately ₹31.5 crore) from Investec Bank Limited, South Africa. This financing is intended to support the working capital requirements for manufacturing and trading Strides SA products. To facilitate this borrowing, Strides Pharma Science Limited provided corporate guarantees in favor of Investec. (cnbctv18.com)

Acquisition of Neviton

Further expanding its technological capabilities, Arco Lab, a subsidiary of Strides Pharma, increased its stake in Neviton to 50% in January 2024. Neviton specializes in Internet of Things (IoT) and engineering solutions, enabling Strides Pharma to enhance its internal digitization processes and offer improved IT services across the group. (capitalmarket.com)

Divestment of Singapore Manufacturing Facility

In December 2023, Strides Pharma Global Pte. Limited completed the sale of its Singapore manufacturing facility to PharmaGend Global Medical Services Pte. Ltd. for USD 15 million. This divestment is part of Strides Pharma’s strategy to optimize its manufacturing network and reduce costs, with the proceeds directed towards debt reduction. (capitalmarket.com)

Response to USFDA Observations

In April 2024, Strides Pharma’s subsidiary, Strides Alathur Private Limited, underwent a routine inspection by the US Food and Drug Administration (USFDA) at its Chennai facility. The inspection concluded with two observations, to which the company has committed to providing comprehensive responses within the stipulated timeframe. Despite these observations, Strides Pharma’s shares reached a 52-week high, reflecting investor confidence in the company’s strategic direction. (cnbctv18.com)

Strategic Partnership with Aspen Pharmacare

In a significant development, Strides Pharma entered into a broad and strategic partnership with Aspen Pharmacare, a leading South African pharmaceutical company. This collaboration aims to leverage combined strengths to enhance the delivery of high-quality, affordable medicines in the region, marking a pivotal step in Strides Pharma’s growth strategy in South Africa. (aspenpharma.com)

These strategic initiatives reflect Strides Pharma’s proactive approach to strengthening its operations and market presence in South Africa, positioning the company for sustained growth and success in the region’s dynamic pharmaceutical landscape.